NCT02166177View on ClinicalTrials.gov

Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

January 22, 2018

Study Completion Date

January 22, 2018

Conditions
End-stage Liver Disease
Interventions
DRUG

Autologous regulatory T cell product

Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.

Trial Locations (1)

Unknown

Kings College Hospital, London

All Listed Sponsors
collaborator

King's College London

OTHER

lead

Guy's and St Thomas' NHS Foundation Trust

OTHER

NCT02166177 - Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients | Biotech Hunter | Biotech Hunter